Table 1.
Summary of clinical studies of prospective antioxidants for AD (Compiled from clinicaltrials.gov)
| Clinical trial number | Interventional agents | Aim | Number of participants and age range (years) | Current status | Primary purpose | Estimated completion date |
|---|---|---|---|---|---|---|
| NCT03514875 | MitoQ | To evaluate the impact of this agent on cerebrovascular blood flow and carotid artery vasodilation | N = 12 Age: 50-85 |
Recruiting | Treatment |
October 2021 |
| NCT03841539 | Mediterranean diet Low fat diet |
To ascertain the effect of these interventions on brain volume and antioxidant level, as well as memory and cardiometabolic biological markers | N = 200 Age: ≥ 65 |
Recruiting | Prevention | February 2023 |
| NCT01982578 | Genistein | To establish the efficacy of this agent in AD | N= 50 Age: ≥ 18 |
Recruiting | Treatment | December 2020 |
| NCT03978052 | Epigallocatechin-gallate plus physical activity plus diet plus mental health promotion | To determine whether this multimodal action can halt cognitive decline | N = 200 Age: 60-80 |
Recruiting | Prevention | September 2021 |
| NCT04740580 | Glutathione (Glycine plus N-acetylcysteine) | To assess the impact of glutathione on cognition | N = 52 Age: 55- 85 |
Recruiting | Other | May 2025 |
| NCT03361410 | Grape powder | To evaluate the impact of this agent on neuropsychological behavior and cerebral metabolism | N = 32 Age: 65 - 85 |
Recruiting | Treatment | January 2021 |
| NCT04063124 | Dasatinib plus Quercetin | To ascertain the penetrance ability of this combined agents in AD individuals | N = 5 Age: ≥ 65 |
Recruiting | Treatment | August 2023 |
| NCT01780974 | Lipoic acid plus omega-3 fatty acids | To evaluate the efficacy of this combined agent in inhibiting AD | N = 42 Age: ≥ 55 |
Completed | Prevention | October 2015 |
| NCT01354444 | Carvedilol | To determine if this agent can ameliorate AD | N = 29 Age: 0 - 100 |
Completed | Treatment | January 2017 |
| NCT01058941 | Lipoic acid plus fish oil concentrate | To ascertain if the combined agent can halt AD progression | N = 67 Age: ≥ 55 |
Completed | Treatment | December 2014 |
| NCT00597376 | Cerefolin NAC | To determine the correlation between this dietary supplement and cognition | N=104 Age: ≥ 60 |
Completed | Prevention | May 2011 |
MitoQ: mitoquinone; AD: Alzheimer disease